Overview
Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)
Status:
Completed
Completed
Trial end date:
2008-10-01
2008-10-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
A Multi-Centered Randomized, Double-Blind, Placebo-Controlled, Phase 2, Exploratory Study to Evaluate the Effect of Rufinamide on Anxiety in Patients with Moderate to Severe Generalized Anxiety Disorder.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Biotie Therapies Inc.Collaborators:
INC Research
Syneos HealthTreatments:
Rufinamide
Criteria
Inclusion Criteria:- Outpatient 18-65
- Meet Diagnostic and Statistical Manual,(DSM) IV criteria for GAD
- Have moderate to severe anxiety
- Sign IRB (Institutional Review Board) approved consent and can comply with visits and
procedures
- Women of childbearing potential must use acceptable method of contraception
Exclusion Criteria:
- Have diagnosis of adjustment disorder or anxiety disorder Not otherwise specified
(NOS)
- Have diagnosis of specific phobia
- Have diagnosis of antisocial personality disorder or other Axis II Disorder
- Have diagnosis of substance abuse disorder within 3 months of study entry
- Have diagnosis of major depressive disorder or panic disorder within 6 months of study
entry
- Have diagnosis of PTSD, eating disorder substance dependence disorder within 12 months
of study entry
- Have diagnosis anytime during lifetime of schizophrenia or other psychotic disorder,
bipolar mood disorder, Obsessive-Compulsive Disorder (OCD), psychosurgery
- Require medication to treat GAD other than study medication
- Failed to show improvement with past treatment for GAD
- Excessively consume caffeine
- Are receiving treatment with prohibited medications
- Uncontrolled thyroid condition
- Positive urine drug screen
- Obese
- Clinically significant ECG finding
- Participating in other clinical trial
- Clinically significant out of range lab value
- Past exposure to rufinamide
- Pregnant or nursing females